```html

Zollinger‑Ellison Syndrome (Duodenal Ulcer) – Comprehensive Guide

Overview

Zollinger‑Ellison syndrome (ZES) is a rare disorder in which one or more tumors—called gastrinomas—form in the pancreas or the duodenum. These neuroendocrine tumors secrete excessive amounts of gastrin, a hormone that stimulates the stomach to produce acid. The resulting hyperacidity leads to refractory peptic ulcers, most commonly in the duodenum, but also in the jejunum, stomach, and even the esophagus.

Who it affects: ZES can occur at any age, but most cases are diagnosed between 30 and 60 years old. Both men and women are affected, with a slight male predominance (approximately 55% male in reported series). About 25–30% of patients have an inherited form associated with the genetic condition multiple endocrine neoplasia type 1 (MEN‑1).

Prevalence: The overall incidence is estimated at 0.5–2 cases per million persons per year, making it one of the rarest causes of peptic ulcer disease. However, among patients with refractory duodenal ulcers (ulcers that do not heal with standard therapy), up to 5% may have ZES.<sup>[1]</sup>

Symptoms

Symptoms result from two main mechanisms: severe gastric acid hypersecretion and the mass effect of the gastrinoma (if the tumor grows large enough). Common symptoms include:

• Abdominal pain – often epigastric, burning, and may worsen 2–3 hours after meals when acid production peaks.
• Diarrhea – watery, sometimes malodorous; occurs in up to 60% of patients due to acid inactivating pancreatic enzymes.
• Heartburn/GERD – reflux is frequent because excess acid overwhelms the lower esophageal sphincter.
• Vomiting – may contain blood if an ulcer has eroded into a blood vessel.
• Weight loss – secondary to malabsorption, chronic diarrhea, and decreased appetite.
• Bleeding ulcers – presentation can include melena (black tarry stools) or hematemesis (vomiting blood).
• Peptic ulcer disease that is refractory – ulcers that persist despite proton‑pump inhibitor (PPI) therapy.
• Steatorrhea – fatty stools due to pancreatic enzyme inactivation.
• Severe, refractory ulcer disease in atypical locations – ulcers beyond the duodenum (e.g., jejunum, ileum).
• Signs of tumor burden (rare): palpable abdominal mass, jaundice (if tumor compresses bile ducts), or metastatic symptoms such as bone pain.

Causes and Risk Factors

Primary cause

ZES is caused by gastrin‑producing neuroendocrine tumors (gastrinomas). Approximately 80% arise in the “gastrinoma triangle” – an anatomical area bounded by the pancreatic head, duodenal–jejunal junction, and the cystic and common bile ducts. The tumors are usually malignant (≈60% metastasize, most often to the liver or regional lymph nodes).

Genetic risk factor

• MEN‑1 syndrome: Autosomal‑dominant mutation of the MEN1 gene; up to 30% of ZES patients have MEN‑1.
• Family history: Rare sporadic familial clustering has been reported.

Other risk modifiers

• Smoking – may increase neuroendocrine tumor risk.
• Chronic gastritis or Helicobacter pylori infection – not a direct cause but can complicate ulcer presentation.

Diagnosis

Because symptoms overlap with common peptic ulcer disease, a high index of suspicion is essential, especially when ulcers are refractory, multiple, or located beyond the duodenum.

Step‑by‑step diagnostic approach

1. Medical History & Physical Examination – detailed review of ulcer course, diarrhea, weight loss, and family history of MEN‑1.
2. Laboratory Tests
   • Fasting serum gastrin level – a level > 1,000 pg/mL (normal < 100 pg/mL) is highly suggestive, especially when coupled with a low gastric pH (< 2).<sup>[2]</sup>
   • Secretin stimulation test – administration of secretin paradoxically raises gastrin in gastrinomas, confirming diagnosis when fasting gastrin is equivocal.
   • Basic metabolic panel, CBC, and liver function tests – assess for anemia, electrolyte disturbances, or metastatic disease.
3. Imaging Studies
   • Endoscopic ultrasound (EUS) – high sensitivity for detecting small pancreatic or duodenal lesions.
   • Multiphasic contrast‑enhanced CT or MRI – delineates tumor size, regional nodes, and distant metastases.
   • Somatostatin‑receptor scintigraphy (Octreoscan) or Gallium‑68 DOTATATE PET/CT – gold standard for locating gastrinomas and metastatic sites because most gastrinomas express somatostatin receptors.
4. Upper Endoscopy (EGD) – visualizes ulcer location, assesses bleeding risk, and obtains biopsies to rule out H. pylori or malignancy.
5. Genetic Testing – recommended for patients with MEN‑1 features or a family history; involves sequencing of the MEN1 gene.

Treatment Options

Management is twofold: control acid hypersecretion and address the gastrinoma (surgical or medical). A multidisciplinary team—gastroenterology, endocrine surgery, oncology, nutrition—optimizes outcomes.

Acid‑Suppression Therapy

• High‑dose Proton Pump Inhibitors (PPIs) – e.g., omeprazole 40–80 mg twice daily or equivalent. PPIs normalize gastric pH, promote ulcer healing, and control diarrhea.<sup>[3]</sup>
• H2‑blockers – generally insufficient alone for ZES but may be added for breakthrough symptoms.

Long‑term PPI use requires monitoring for hypomagnesemia, vitamin B12 deficiency, and bone density loss.

Surgical Treatment

Surgery offers the only potential cure, especially for localized disease.

• Enucleation – removal of a single, well‑circumscribed gastrinoma without removing surrounding pancreatic tissue; suitable for tumors < 2 cm without nodal involvement.
• Pancreaticoduodenectomy (Whipple procedure) – indicated for larger duodenal or pancreatic head tumors, or when regional lymph nodes are involved.
• Debulking surgery – reduces tumor burden in metastatic disease to improve symptom control; often combined with medical therapy.

Medical Therapy for Unresectable or Metastatic Disease

• Somatostatin analogues (octreotide, lanreotide) – inhibit gastrin release and may shrink tumors.
• Targeted therapy – everolimus (an mTOR inhibitor) or sunitinib (a tyrosine‑kinase inhibitor) approved for progressive pancreatic neuroendocrine tumors.
• Peptide receptor radionuclide therapy (PRRT) – ^177Lu‑DOTATATE delivers radiation directly to somatostatin‑receptor‑positive tumors; shows durable disease control in many series.
• Chemotherapy – reserved for high‑grade, rapidly progressive disease; regimens may include streptozocin + 5‑FU or temozolomide.

Lifestyle & Adjunct Measures

• Avoid NSAIDs, aspirin, and other ulcer‑irritating drugs.
• Limit alcohol and caffeine, which stimulate acid secretion.
• Small, frequent meals can reduce post‑prandial acid spikes.
• Supplement magnesium, calcium, and vitamin B12 if on long‑term PPIs.

Living with Zollinger‑Ellison Syndrome (duodenal ulcer)

While ZES is chronic, many patients achieve good symptom control and normal life expectancy with appropriate therapy.

Daily Management Tips

1. Medication adherence – take PPIs exactly as prescribed; never skip doses.
2. Regular monitoring – schedule labs (magnesium, calcium, B12) every 6–12 months and imaging annually to assess tumor status.
3. Dietary considerations – a low‑acid, low‑fat diet reduces duodenal irritation. Include lean proteins, whole grains, and non‑citrus fruits.
4. Hydration – maintain adequate fluid intake to offset diarrhea‑related losses.
5. Stress management – chronic disease can be psychologically taxing; consider counseling or support groups.
6. Vaccinations – stay up‑to‑date on hepatitis B, pneumococcal, and influenza vaccines, especially if receiving immunosuppressive therapy.
7. Activity – regular moderate exercise improves gastrointestinal motility and bone health.

Follow‑up Schedule

• Every 3–6 months: Clinical review, symptom questionnaire, and blood work.
• Annually: Cross‑sectional imaging (CT/MRI) or functional imaging (DOTATATE PET) to detect recurrence or metastasis.
• Every 2–3 years: Endoscopic surveillance for ulcer healing and to screen for H. pylori.

Prevention

Because ZES is primarily driven by tumor biology, primary prevention is limited. However, the following measures can reduce secondary ulcer risk and improve overall health:

• Quit smoking – lowers the risk of neuroendocrine tumor progression.
• Avoid chronic use of NSAIDs or high‑dose aspirin.
• Screen for and eradicate Helicobacter pylori infection, which can exacerbate ulcer disease.
• For individuals with MEN‑1, undergo genetic counseling and regular surveillance for pancreatic neuroendocrine tumors.

Complications

If untreated or poorly controlled, ZES can lead to serious, sometimes life‑threatening complications:

• Bleeding ulcer – may require endoscopic hemostasis, transfusion, or surgery.
• Perforation – a hole in the duodenum can cause peritonitis, a surgical emergency.
• Obstruction – edema or tumor growth can block the duodenum, causing vomiting and malnutrition.
• Severe malabsorption – chronic diarrhea and steatorrhea can lead to weight loss, electrolyte imbalance, and deficiency of fat‑soluble vitamins.
• Metastatic disease – liver, lymph nodes, bone, or lung spread reduces survival; median overall survival for metastatic ZES is roughly 8–10 years with modern therapy.<sup>[4]</sup>
• Gastric neuroendocrine (carcinoid) tumors – chronic hypergastrinemia can stimulate enterochromaffin‑like cells, leading to secondary gastric carcinoids.

When to Seek Emergency Care

References

1. Mayo Clinic. “Zollinger‑Ellison syndrome.” Updated 2023. https://www.mayoclinic.org
2. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Zollinger‑Ellison Syndrome.” 2022. https://www.niddk.nih.gov
3. Cleveland Clinic. “Treatment of Zollinger‑Ellison syndrome.” 2024. https://my.clevelandclinic.org
4. Kulke MH, et al. “Neuroendocrine Tumors: Updates on Epidemiology, Diagnosis, and Management.” J Clin Oncol. 2023;41(15):2170‑2180. DOI:10.1200/JCO.22.02057.

```